trending Market Intelligence /marketintelligence/en/news-insights/trending/bnSU0baXGAzX8L6metfHpw2 content esgSubNav
In This List

NuCana forced to suspend study for pancreatic cancer drug

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


NuCana forced to suspend study for pancreatic cancer drug

NuCana PLC stopped bringing in new patients for a late-stage pancreatic cancer study after an analysis deemed that the trial would not be successful.

NuCana's drug Acelarin was developed as a chemotherapy treatment for metastatic pancreatic cancer.

The U.K. company was told by the Independent Safety and Data Monitoring Committee that the objective designed at the outset of the study was likely unobtainable according to interim data.

The sponsor of the study, the Clatterbridge Cancer Centre, suspended the study to review the data and decide whether to resume it. So far, 25 patients have received the drug, according to an Aug. 20 release from NuCana.

"When we agreed to provide Acelarin for this investigator-sponsored study, we were well aware of the challenges of treating patients with metastatic pancreatic cancer," NuCana CEO Hugh Griffith said.